SCHEMBL4605553

SCHEMBL4605553

S=C(C1=NN(c2ccc(Cl)cc2Cl)C(c2ccc(Cl)cc2)C1)N1CCCCCCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.58
CNR1 P21554 6/20 0.58
LMNA P02545 2/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
HPGD P15428 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
PKM P14618 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PHGDH O43175 1/20 0.38
EGFR P00533 1/20 0.38
PRKCZ Q05513 3/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4605163 1.00 CNR2 (0.58) CNR2CNR1LMNANPC1RAB9A
SCHEMBL8453029 0.94 CNR2 (0.52) CNR2CNR1LMNANPC1RAB9A
SCHEMBL8469991 0.91 CNR2 (0.49) CNR2CNR1EGFRPRKCZMAOA
SCHEMBL4607380 0.89 CNR1 (0.61) CNR2CNR1NPC1RAB9AHPGD
SCHEMBL2018135 0.89 CNR1 (0.61) CNR2CNR1NPC1RAB9AHPGD
SCHEMBL2288238 0.89 CNR1 (0.61) CNR2CNR1NPC1RAB9AHPGD
SCHEMBL4607208 0.86 CNR1 (0.66) CNR2CNR1
SCHEMBL4606282 0.86 CNR1 (0.66) CNR2CNR1
SCHEMBL4605360 0.85 CNR1 (0.59) CNR2CNR1EGFRPRKCZMAOA
SCHEMBL2015954 0.85 CNR2 (0.62) CNR2CNR1LMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP claimed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP claimed
EP-1743887-A1 Thiocarbonyl-substituted pyrazoline compounds, their preparation and use as CB1 modulators LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP claimed
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
WO-2007009688-A1 THIOCARBONYL-SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-25 WO disclosed
EP-1743887-A1 Thiocarbonyl-substituted pyrazoline compounds, their preparation and use as CB1 modulators LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP disclosed
EP-1743887-A1 Thiocarbonyl-substituted pyrazoline compounds, their preparation and use as CB1 modulators LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP disclosed